scholarly journals Efficacy and safety of PDE5 inhibitors in the treatment of diabetes mellitus erectile dysfunction

Medicine ◽  
2018 ◽  
Vol 97 (40) ◽  
pp. e12559 ◽  
Author(s):  
Xiao Li ◽  
Qi Zhao ◽  
Jingshang Wang ◽  
Jisheng Wang ◽  
Hengheng Dai ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Efficacy And Safety ◽  
Pde5 Inhibitors ◽  
Treatment Of Diabetes

scholarly journals Efficacy and safety of PDE5 inhibitors in the treatment of diabetes mellitus erectile dysfunction: a systematic review and meta-analysis

2019 ◽  
Author(s):  
Xiao Li ◽  
Qi Zhao ◽  
Jingshang Wang ◽  
Jisheng Wang ◽  
Hengheng Dai ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Erectile Function ◽  
Assessment Tool ◽  
Meta Analysis ◽  
Knowledge Network ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
Pde5 Inhibitors ◽  
Data Resource

Abstract ABSTRACT Background: To systematically evaluate the efficacy and safety of the PDE5 inhibitors in patients with diabetes mellitus erectile dysfunction (DMED). Methods:Random control trials (RCTs) in PubMed, EMBASE, Cochrane library, ClinicalTrials, China Knowledge Network (CNKI), Weipu Chinese Science and Technology Journal Full-text Database (VIP), Wanfang Data Resource System (WANFANG) were searched. Two researchers independently screened the literature, extracted the data and checked the results, and used the risk assessment tool to conduct a methodological quality assessment, and finally conducted a meta-analysis. The primary outcome, the erectile function scores of the International Index of Erectile Dysfunction (IIEF-EF), was recorded, while secondary outcomes (IIEF-Q3, IIEF-Q4, SEP 2 and 3, GAQ) and safety outcomes also needed attention. Results: Twelve studies included 3,124 patients and six PDE5 inhibitors were included. Compared with placebo, PDE5 inhibitors significantly improved male erectile function in IIEF-EF (WMD = 5.73; 95% CI: 3.62 to 7.84), IIEF-Q3 (WMD = 1.14; 95% CI: 0.87 to 1.40), IIEF-Q4 (WMD=1.28; 95% CI: 1.04 to 1.51), SEP2 (WMD=21.24; 95% CI: 15.50 to 26.98), SEP3 (WMD=25.77; 95% CI: 18.78 to 32.77), GAQ (RR) =2.98; 95% CI: 2.06 to 4.32), and with the safety (WMD=5.73; 95% CI: 3.62 to 7.84). Conclusions: PDE5 inhibitors can significantly improve the patient's erectile function, but cannot ignore their side effects.

EFFICACY AND SAFETY OF TADALAFIL 2.5 MG AND 5 MG ADMINISTERED ONCE A DAY IN MEN WITH DIABETES MELLITUS AND ERECTILE DYSFUNCTION

2006 ◽  
Vol 5 (2) ◽  
pp. 139 ◽  
Author(s):  
G. Brock ◽  
J. Buvat ◽  
M. Gambla ◽  
D. Hatzichristou ◽  
D. Lording ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Efficacy And Safety

scholarly journals The safety and efficacy of PDE5-inhibitors-vardenafil on treating diabetes mellitus erectile dysfunction

Medicine ◽  
2019 ◽  
Vol 98 (51) ◽  
pp. e18361
Author(s):  
Jia He ◽  
Xiao Li ◽  
Heng-Heng Dai ◽  
Ji-Sheng Wang ◽  
Hai-Song Li ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Pde5 Inhibitors ◽  
Safety And Efficacy

scholarly journals Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 8 (4) ◽  
pp. 47
Author(s):  
Api Chewcharat ◽  
Narut Prasitlumkum ◽  
Charat Thongprayoon ◽  
Tarun Bathini ◽  
Juan Medaura ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Blood Pressure ◽  
Body Weight ◽  
Kidney Transplant ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Transplant Patients ◽  
Treatment Of Diabetes ◽  
Kidney Transplant Patients

Background: The objective of this systematic review was to evaluate the efficacy and safety profiles of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for treatment of diabetes mellitus (DM) among kidney transplant patients. Methods: We conducted electronic searches in Medline, Embase, Scopus, and Cochrane databases from inception through April 2020 to identify studies that investigated the efficacy and safety of SGLT-2 inhibitors in kidney transplant patients with DM. Study results were pooled and analyzed utilizing random-effects model. Results: Eight studies with 132 patients (baseline estimated glomerular filtration rate (eGFR) of 64.5 ± 19.9 mL/min/1.73 m2) treated with SGLT-2 inhibitors were included in our meta-analysis. SGLT-2 inhibitors demonstrated significantly lower hemoglobin A1c (HbA1c) (WMD = −0.56% [95%CI: −0.97, −0.16]; p = 0.007) and body weight (WMD = −2.16 kg [95%CI: −3.08, −1.24]; p < 0.001) at end of study compared to baseline level. There were no significant changes in eGFR, serum creatinine, urine protein creatinine ratio, and blood pressure. By subgroup analysis, empagliflozin demonstrated a significant reduction in body mass index (BMI) and body weight. Canagliflozin revealed a significant decrease in HbA1C and systolic blood pressure. In terms of safety profiles, fourteen patients had urinary tract infection. Only one had genital mycosis, one had acute kidney injury, and one had cellulitis. There were no reported cases of euglycemic ketoacidosis or acute rejection during the treatment. Conclusion: Among kidney transplant patients with excellent kidney function, SGLT-2 inhibitors for treatment of DM are effective in lowering HbA1C, reducing body weight, and preserving kidney function without reporting of serious adverse events, including euglycemic ketoacidosis and acute rejection.

scholarly journals Assessment of the efficacy of α-lipoic acid in treatment of diabetes mellitus patients with erectile dysfunction

Medicine ◽  
2020 ◽  
Vol 99 (36) ◽  
pp. e22161
Author(s):  
Jiawei Cai ◽  
Junmin Chen ◽  
Qianqian Zeng ◽  
Jie Liu ◽  
Yanli Zhang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Lipoic Acid ◽  
Treatment Of Diabetes

Tadalafil versus sildenafil citrate in the treatment of ED: Italian patients’ preferences and explanatory notes

2008 ◽  
Vol 75 (1) ◽  
pp. 24-31 ◽  
Author(s):  
F. Fusco ◽  
A. Lembo ◽  
G.M. Ludovico ◽  
F. Pirozzi Farina ◽  
F. Montorsi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Erectile Dysfunction ◽  
Crossover Study ◽  
Sexual Intercourse ◽  
Alternative Treatment ◽  
Sildenafil Citrate ◽  
Treatment Preference ◽  
Efficacy And Safety ◽  
Pde5 Inhibitors ◽  
Randomized Crossover Study

This is an open, multicentre, randomized, crossover study having the aim to evaluate the preference for sildenafil citrate or tadalafil in a population of Italian patients affected by ED, and to compare the efficacy and safety of these two drugs. Material and Methods. From October 2003 to November 2004, thirteen Italian centers enrolled ED patients (age >18) being in steady and naïve relation to ED treatment, both through PDE5 inhibitors and any other treatment option. These patients were randomized to sildenafil or tadalafil for 12 weeks, after which they were switched to the alternative treatment for a further 12 weeks. The preference was evaluated through the Treatment Preference Question (TPQ): “During this clinical trial you have taken tadalafil and sildenafil for the treatment of erectile dysfunction. Which medication do you prefer to take for the next 8 weeks of treatment?”. Moreover, patients were asked to express their preference as “strong” or “moderate” and to answer some questions to clarify the reasons behind their preference. SEP and IIEF-EF questionnaires were used for a comparison of efficacy. Results. 167 patients were enrolled, 144 of whom completed both treatment periods. On being asked the TPQ, 75% of patients (n=108) decided to continue treatment with tadalafil, in particular because it made it possible to have an erection many hours after taking the medication (first or second preference reason for 64.8% of patients), while 25% (n=36) preferred sildenafil (p=0.001). Both drugs improved the IIEF-EF and SEP scores compared to baseline, with a slightly but significantly greater improvement with tadalafil for both parameters. Conclusions. Tadalafil and sildenafil are both effective and well tolerated. Most of the patients prefer tadalafil thanks to the possibility of having sexual intercourse many hours after taking the medication.

Sign in / Sign up

Export Citation Format

Share Document